Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAPREV-IT Diabetes Prevention Immune Tolerance
2008-007484-16Phase 2Completed
- Sponsor
- Helena Elding Larsson
- Start
- Dec 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of Diamyd in diabetes mellitus type 1 (T1D), sponsored by Helena Elding Larsson. Primary endpoint: Safety of Diamyd in children at risk for type 1 diabetes. Started Dec 2008; status: completed.
02
Drugs
Diamyd
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2008-007484-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007484-16.